Log in

NASDAQ:URGN - Urogen Pharma Stock Price, Forecast & News

$28.06
+0.03 (+0.11 %)
(As of 02/17/2020 04:15 AM ET)
Add
Today's Range
$27.41
Now: $28.06
$28.81
50-Day Range
$28.03
MA: $31.28
$34.60
52-Week Range
$20.72
Now: $28.06
$42.32
Volume75,363 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:URGN
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees70
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.


Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How were Urogen Pharma's earnings last quarter?

Urogen Pharma Ltd (NASDAQ:URGN) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.06) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.26) by $0.20. View Urogen Pharma's Earnings History.

When is Urogen Pharma's next earnings date?

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Urogen Pharma.

What price target have analysts set for URGN?

8 analysts have issued 12-month price targets for Urogen Pharma's stock. Their forecasts range from $37.00 to $75.00. On average, they anticipate Urogen Pharma's share price to reach $50.14 in the next year. This suggests a possible upside of 78.7% from the stock's current price. View Analyst Price Targets for Urogen Pharma.

What is the consensus analysts' recommendation for Urogen Pharma?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.

What are Wall Street analysts saying about Urogen Pharma stock?

Here are some recent quotes from research analysts about Urogen Pharma stock:
  • 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (2/7/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating after URGN’s investor day as we came away more bullish on UGN-101 as a treatment for LG-UTUC based on commentary from the physician panel which we believe did a good job addressing many of the investor concerns we hear. Additionally, URGN also reported encouraging results for UGN-102 in LG-NMIBC. While we concede LG-UTUC is a small market, we think investors are meaningfully discounting UGN-101’s commercial potential in the face of the clear unmet need for a non-surgical, kidney sparing treatment which was highlighted by the panel. UGN-101 has a high probability of approval, in our view, though we think shares could be range bound until approval/ launch, likely in 1H20." (9/24/2019)

Has Urogen Pharma been receiving favorable news coverage?

News coverage about URGN stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urogen Pharma earned a news sentiment score of 1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Urogen Pharma.

Are investors shorting Urogen Pharma?

Urogen Pharma saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,120,000 shares, an increase of 17.8% from the January 15th total of 1,800,000 shares. Based on an average daily trading volume, of 179,400 shares, the short-interest ratio is currently 11.8 days. Currently, 12.5% of the company's stock are short sold. View Urogen Pharma's Current Options Chain.

What other stocks do shareholders of Urogen Pharma own?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the folowing people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
  • Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
  • Mr. Stephen Mullennix, Chief Operating Officer
  • Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are Urogen Pharma's major shareholders?

Urogen Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wildcat Capital Management LLC (5.53%), Migdal Insurance & Financial Holdings Ltd. (3.53%), Credit Suisse AG (3.20%), State Street Corp (1.97%), FMR LLC (1.51%) and Meitav Dash Investments Ltd. (1.30%). Company insiders that own Urogen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Institutional Ownership Trends for Urogen Pharma.

Which major investors are selling Urogen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Migdal Insurance & Financial Holdings Ltd., Goldman Sachs Group Inc., Bank Hapoalim BM, Private Advisors LLC, New York State Common Retirement Fund, Victory Capital Management Inc. and Quantbot Technologies LP. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Insider Buying and Selling for Urogen Pharma.

Which major investors are buying Urogen Pharma stock?

URGN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Wildcat Capital Management LLC, Jane Street Group LLC, Credit Suisse AG, State Street Corp, Meitav Dash Investments Ltd., California Public Employees Retirement System and UBS Asset Management Americas Inc.. Company insiders that have bought Urogen Pharma stock in the last two years include Elizabeth A Barrett and Mark Schoenberg. View Insider Buying and Selling for Urogen Pharma.

How do I buy shares of Urogen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $28.06.


MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Pattern Day Trader

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel